Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Henrikson NB, Aiello Bowles EJ, Blasi PR, Morrison CC, Nguyen M, Pillarisetty VG, Lin JS.

JAMA. 2019 Aug 6;322(5):445-454. doi: 10.1001/jama.2019.6190.

PMID:
31386140
2.

Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.

Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM.

Cancer Immunol Res. 2019 Aug;7(8):1237-1243. doi: 10.1158/2326-6066.CIR-18-0940. Epub 2019 Jun 6.

PMID:
31171504
3.

Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer.

Seo YD, Jiang X, Sullivan KM, Jalikis FG, Smythe KS, Abbasi A, Vignali M, Park JO, Daniel SK, Pollack SM, Kim TS, Yeung R, Crispe IN, Pierce RH, Robins H, Pillarisetty VG.

Clin Cancer Res. 2019 Jul 1;25(13):3934-3945. doi: 10.1158/1078-0432.CCR-19-0081. Epub 2019 Apr 2.

PMID:
30940657
4.

Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.

Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG.

Clin Transl Med. 2019 Apr 1;8(1):10. doi: 10.1186/s40169-019-0226-9. Review.

5.

Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG.

Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, Lahat G, Strauss DC, Gonzalez R, Ahuja N, Grignani G, Quagliuolo V, Stoeckle E, De Paoli A, Pillarisetty VG, Nessim C, Swallow CJ, Bagaria S, Canter R, Mullen J, Gelderblom HJ, Pennacchioli E, van Coevorden F, Cardona K, Fiore M, Fairweather M, Gronchi A.

Clin Cancer Res. 2019 Apr 15;25(8):2664-2671. doi: 10.1158/1078-0432.CCR-18-2700. Epub 2019 Feb 5.

PMID:
30723141
6.

Standardization of perioperative care facilitates safe discharge by postoperative day five after pancreaticoduodenectomy.

Daniel SK, Thornblade LW, Mann GN, Park JO, Pillarisetty VG.

PLoS One. 2018 Dec 28;13(12):e0209608. doi: 10.1371/journal.pone.0209608. eCollection 2018.

7.

Establishment of Slice Cultures as a Tool to Study the Cancer Immune Microenvironment.

Jiang X, Seo YD, Sullivan KM, Pillarisetty VG.

Methods Mol Biol. 2019;1884:283-295. doi: 10.1007/978-1-4939-8885-3_20.

PMID:
30465211
8.

Precision oncology in liver cancer.

Sullivan KM, Kenerson HL, Pillarisetty VG, Riehle KJ, Yeung RS.

Ann Transl Med. 2018 Jul;6(14):285. doi: 10.21037/atm.2018.06.14. Review.

9.

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. doi: 10.6004/jnccn.2018.0056.

PMID:
29891520
10.

Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy.

Maloney E, Khokhlova T, Pillarisetty VG, Schade GR, Repasky EA, Wang YN, Giuliani L, Primavera M, Hwang JH.

Int Rev Immunol. 2017 Nov 2;36(6):338-351. doi: 10.1080/08830185.2017.1363199. Epub 2017 Sep 29. Review.

11.

Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment.

Jiang X, Seo YD, Chang JH, Coveler A, Nigjeh EN, Pan S, Jalikis F, Yeung RS, Crispe IN, Pillarisetty VG.

Oncoimmunology. 2017 May 25;6(7):e1333210. doi: 10.1080/2162402X.2017.1333210. eCollection 2017.

12.

Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer.

Chen R, Lai LA, Sullivan Y, Wong M, Wang L, Riddell J, Jung L, Pillarisetty VG, Brentnall TA, Pan S.

Sci Rep. 2017 Aug 11;7(1):7950. doi: 10.1038/s41598-017-08436-6.

13.

T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL.

Cancer. 2017 Sep 1;123(17):3291-3304. doi: 10.1002/cncr.30726. Epub 2017 May 2.

14.

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.

Smith TT, Moffett HF, Stephan SB, Opel CF, Dumigan AG, Jiang X, Pillarisetty VG, Pillai SPS, Wittrup KD, Stephan MT.

J Clin Invest. 2017 Jun 1;127(6):2176-2191. doi: 10.1172/JCI87624. Epub 2017 Apr 24.

15.

The Imaging and Pathological Features of Metastatic Leiomyosarcoma in the Gallbladder.

Guo Y, Chen E, Davidson DJ, Pillarisetty VG, Jones RL, Pollack SM.

Rare Tumors. 2016 Dec 23;8(4):6618. doi: 10.4081/rt.2016.6618. eCollection 2016 Nov 17.

16.

Role of immune cells in pancreatic cancer from bench to clinical application: An updated review.

Chang JH, Jiang Y, Pillarisetty VG.

Medicine (Baltimore). 2016 Dec;95(49):e5541. Review.

17.

T-cell programming in pancreatic adenocarcinoma: a review.

Seo YD, Pillarisetty VG.

Cancer Gene Ther. 2017 Mar;24(3):106-113. doi: 10.1038/cgt.2016.66. Epub 2016 Dec 2. Review.

PMID:
27910859
18.

γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation.

Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, Mani VRK, Avanzi A, Tippens D, Narayanan R, Jang JE, Newman E, Pillarisetty VG, Dustin ML, Bar-Sagi D, Hajdu C, Miller G.

Cell. 2016 Sep 8;166(6):1485-1499.e15. doi: 10.1016/j.cell.2016.07.046. Epub 2016 Aug 25.

19.

Efficacy and cost of robotic hepatectomy: is the robot cost-prohibitive?

Sham JG, Richards MK, Seo YD, Pillarisetty VG, Yeung RS, Park JO.

J Robot Surg. 2016 Dec;10(4):307-313. Epub 2016 May 6.

PMID:
27153838
20.

Pancreatic intraductal papillary mucinous neoplasm in a patient with Lynch syndrome.

Flanagan MR, Jayaraj A, Xiong W, Yeh MM, Raskind WH, Pillarisetty VG.

World J Gastroenterol. 2015 Mar 7;21(9):2820-5. doi: 10.3748/wjg.v21.i9.2820.

21.

The pancreatic cancer microenvironment: an immunologic battleground.

Pillarisetty VG.

Oncoimmunology. 2014 Aug 3;3(8):e950171. eCollection 2014.

22.

Neuroendocrine tumors, version 1.2015.

Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Jan;13(1):78-108.

PMID:
25583772
23.

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU 3rd, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C.

J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014.

24.

FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasis.

Jiang Y, Du Z, Yang F, Di Y, Li J, Zhou Z, Pillarisetty VG, Fu D.

PLoS One. 2014 Sep 5;9(9):e106741. doi: 10.1371/journal.pone.0106741. eCollection 2014.

25.

Choledochal cysts: a clinicopathologic study of 36 cases with emphasis on the morphologic and the immunohistochemical features of premalignant and malignant alterations.

Katabi N, Pillarisetty VG, DeMatteo R, Klimstra DS.

Hum Pathol. 2014 Oct;45(10):2107-14. doi: 10.1016/j.humpath.2014.06.016. Epub 2014 Jul 2.

PMID:
25123074
26.

The prognostic value of liver tumor T cell infiltrates.

Khan H, Pillarisetty VG, Katz SC.

J Surg Res. 2014 Sep;191(1):189-95. doi: 10.1016/j.jss.2014.06.001. Epub 2014 Jun 7. Review.

27.

Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.

Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, Pillarisetty VG.

PLoS One. 2014 May 2;9(5):e96565. doi: 10.1371/journal.pone.0096565. eCollection 2014.

28.

A contemporary large single-institution evaluation of resected retroperitoneal sarcoma.

Bremjit PJ, Jones RL, Chai X, Kane G, Rodler ET, Loggers ET, Pollack SM, Pillarisetty VG, Mann GN.

Ann Surg Oncol. 2014 Jul;21(7):2150-8. doi: 10.1245/s10434-014-3616-7. Epub 2014 Mar 11.

PMID:
24615180
29.

Immunotherapy for solid tumors--a review for surgeons.

Saied A, Pillarisetty VG, Katz SC.

J Surg Res. 2014 Apr;187(2):525-35. doi: 10.1016/j.jss.2013.12.018. Epub 2013 Dec 25. Review.

30.

The use of radiofrequency ablation in gastrointestinal stromal tumor.

Pollack SM, Pillarisetty VG, Padia SA, Jones RL.

J Vasc Interv Radiol. 2013 May;24(5):751. doi: 10.1016/j.jvir.2013.02.026. No abstract available.

PMID:
23622046
31.

Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases.

Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, DeMatteo RP.

Ann Surg Oncol. 2013 Mar;20(3):946-55. doi: 10.1245/s10434-012-2668-9. Epub 2012 Sep 26.

32.

Neuroendocrine tumors.

Kulke MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA; National Comprehensive Cancer Networks.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):724-64.

PMID:
22679117
33.

T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases.

Katz SC, Donkor C, Glasgow K, Pillarisetty VG, Gönen M, Espat NJ, Klimstra DS, D'Angelica MI, Allen PJ, Jarnagin W, Dematteo RP, Brennan MF, Tang LH.

HPB (Oxford). 2010 Dec;12(10):674-83. doi: 10.1111/j.1477-2574.2010.00231.x.

34.

Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection.

Park J, Pillarisetty VG, Brennan MF, Jarnagin WR, D'Angelica MI, Dematteo RP, G Coit D, Janakos M, Allen PJ.

J Am Coll Surg. 2010 Sep;211(3):308-15. doi: 10.1016/j.jamcollsurg.2010.05.008. Epub 2010 Jul 14.

PMID:
20800186
35.

Randomized clinical trials in gastric cancer.

Mezhir JJ, Pillarisetty VG, Shah MA, Coit DG.

Surg Oncol Clin N Am. 2010 Jan;19(1):81-100. doi: 10.1016/j.soc.2009.09.011. Review.

PMID:
19914561
36.

Micromedullary thyroid cancer: how micro is truly micro?

Pillarisetty VG, Katz SC, Ghossein RA, Tuttle RM, Shaha AR.

Ann Surg Oncol. 2009 Oct;16(10):2875-81. doi: 10.1245/s10434-009-0595-1. Epub 2009 Jul 1.

PMID:
19568813
37.

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis.

Gammon DC, Dutton T, Piperdi B, Zybert J, Wolfe SH, Nguyen E, Sbat D, Pillarisetty VG, Sullivan M, Whalen GF.

Am J Health Syst Pharm. 2009 Jul 1;66(13):1186-90. doi: 10.2146/ajhp080019.

PMID:
19535657
38.

CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis.

Burt BM, Plitas G, Stableford JA, Nguyen HM, Bamboat ZM, Pillarisetty VG, DeMatteo RP.

J Leukoc Biol. 2008 Oct;84(4):1039-46. doi: 10.1189/jlb.0408256. Epub 2008 Jul 29.

39.

Biliary obstruction selectively expands and activates liver myeloid dendritic cells.

Bleier JI, Katz SC, Chaudhry UI, Pillarisetty VG, Kingham TP 3rd, Shah AB, Raab JR, DeMatteo RP.

J Immunol. 2006 Jun 15;176(12):7189-95.

40.

In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells.

Chaudhry UI, Katz SC, Kingham TP, Pillarisetty VG, Raab JR, Shah AB, DeMatteo RP.

FASEB J. 2006 May;20(7):982-4. Epub 2006 Mar 29.

PMID:
16571772
41.

Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors.

Katz SC, Pillarisetty VG, Bleier JI, Kingham TP, Chaudhry UI, Shah AB, DeMatteo RP.

Hepatology. 2005 Aug;42(2):293-300.

PMID:
16025518
42.
43.

Liver sinusoidal endothelial cells are insufficient to activate T cells.

Katz SC, Pillarisetty VG, Bleier JI, Shah AB, DeMatteo RP.

J Immunol. 2004 Jul 1;173(1):230-5.

44.

Increased and long-term generation of dendritic cells with reduced function from IL-6-deficient bone marrow.

Bleier JI, Pillarisetty VG, Shah AB, DeMatteo RP.

J Immunol. 2004 Jun 15;172(12):7408-16.

45.

Natural killer cell depletion confounds the antitumor mechanism of endogenous IL-12 overexpression.

Miller G, Bleier JI, Antonescu C, Pillarisetty VG, Shah AB, Lahrs S, DeMatteo RP.

Int J Cancer. 2004 Jun 20;110(3):395-402.

46.

Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition.

Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP.

J Immunol. 2004 Jan 15;172(2):1009-17.

47.

Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties.

Miller G, Pillarisetty VG, Shah AB, Lahrs S, DeMatteo RP.

J Immunol. 2003 Apr 1;170(7):3554-64.

48.

GM-CSF expands dendritic cells and their progenitors in mouse liver.

Pillarisetty VG, Miller G, Shah AB, DeMatteo RP.

Hepatology. 2003 Mar;37(3):641-52.

PMID:
12601362
49.

Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection.

Miller G, Lahrs S, Pillarisetty VG, Shah AB, DeMatteo RP.

Cancer Res. 2002 Sep 15;62(18):5260-6.

Supplemental Content

Loading ...
Support Center